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tion. These assays are readily appli-
cable for small-scale analysis, induc-
tive screening, and if necessary, for
regional population studies. Caution
must be exercised to limit false neg-
atives by minimizing the gap be-
tween assay primers. Although spe-
cific base changes may be associated
with melting signatures, confirma-
tion requires sequencing of PCR
products. We reduced the likelihood
of false positives arising in this man-
ner by ruling out the presence of
sequence variants in the region being
interrogated within the population
under study. Nevertheless, in un-
known populations, we recommend
conducting sequencing in a limited
number of individuals to verify the
basis for melting curve profiles of the
variants being screened.
References
1. Brusilow SW, Horwich AL. Urea cycle enzymes.
In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds.
The Metabolic and Molecular Bases of Inherited
Disease, 8th ed. New York: McGraw-Hill, 2001;
1909–64.
2. Alsayed M, AlAhmed S, Alsmadi O, Khalil H,
Rashed M, Imtiaz F, et al. Identification of a
common novel mutation in Saudi patients with
Argininosuccinic aciduria. J Inherit Metab Dis
2005;28:877–83.
3. Rashed MS, Rahbeeni Z, Ozand PT. Application
of electrospray tandem mass spectrometry to
neonatal screening. Semin Perinatol 1999;23:
183–93.
4. Faull K, Bolton P, Halpern B, Hammond J, Danks
DM, Hahnel R, et al. Patient with defect in
leucine metabolism [Letter]. New Engl J Med
1976;294:1013.
5. Ozand PT, Devol EB, Gascon GG. Neurometa-
bolic diseases at a national referral center: five
years experience at the King Faisal Specialist
Hospital and Research Centre. J Child Neurol
1992;7(Suppl):S4–11.
6. Mitchell GA, Ozand PT, Robert M-F, Ashmarina L,
Roberts J, Gibson KM, et al. HMG CoA lyase
deficiency: identification of five causal point
mutations in codons 41 and 42, including a
frequent Saudi Arabian mutation, R41Q. Am J
Hum Genet 1998;62:295–300.
7. Liew M, Pryor R, Palais R, Meadows C, Erali M,
Lyon E, et al. Genotyping of single-nucleotide
polymorphisms by high-resolution melting of
small amplicons. Clin Chem 2004;50:1156–
64.
8. Santalucia J. A unified view of polymer, dumb-
bell, and oligonucleotide DNA nearest-neighbor
thermodynamics. Proc Natl Acad Sci U S A
1998;95:1460–5.
9. Sugimoto N, Nakano S, Yoneyama M, Honda K.
Improved thermodynamic parameters and helix
initiation factor to predict stability of DNA du-
plexes. Nucleic Acids Res 1996;24:4501–5.
Osama Alsmadi1*
Fadi Alkayal1
MoeenAldeen Al-Sayed2
Mohamed S. Rashed2,3
Faiqa Imtiaz1
Brian F. Meyer1
1 Arabian Diagnostics Laboratory
Research Centre
2 Department Of Medical Genetics
and
3 National Laboratory for Newborn
Screening
King Faisal Specialist Hospital
and Research Center
Riyadh, Saudi Arabia
* Address correspondence to this au-
thor at: Arabian Diagnostics Laboratory,
MBC 03, KFSHRC, PO Box 3354, Riyadh
11211, Saudi Arabia. Fax 966-1205-5171;
e-mail oalsmadi@kfshrc.edu.sa.
DOI: 10.1373/clinchem.2006.067538
Survivin and MKI67 mRNA Expression
in Bladder Washings of Patients with
Superficial Urothelial Cell Carcinoma
Correlate with Tumor Stage and
Grade but Do Not Predict Tumor
Recurrence
To the Editor:
Seventy percent of patients with su-
perficial urothelial cell carcinoma de-
velop recurrences after transurethral
resection of the primary tumor. Be-
cause recurrence prediction on the
basis of tumor size, grade, and mul-
tiplicity is unreliable, all patients
need regular bladder examination
with cystoscopy. An accurate
method to differentiate between pa-
tients with short or long recurrence-
free periods might reduce the num-
ber of invasive cystoscopies in a
subgroup of patients.
The gene MKI67 (proliferation
marker antigen identified by the
monoclonal antibody Ki-67) and the
antiapoptosis gene survivin are
promising prognostic markers, be-
cause increased MKI67 and survivin
mRNA concentrations indicate short
recurrence-free periods (1–4). In ad-
dition to the presence of survivin
mRNA in tumor tissue, we observed
a relationship between early tumor
recurrence and increased concentra-
tions of survivin mRNA in bladder
washings (5 ). Bladder washings are
easily obtained during cystoscopy
and generally reflect the molecular
biological status of the urothelium
(6, 7).
To confirm our previous findings
regarding survivin and to investigate
the recurrence-predictive value of
MKI67 mRNA, we collected 95 blad-
Fig. 1. Derivative melting curve analysis for HMGCL:p.R41Q and ASL:p.Q354STOP.
LCGreen I assays were carried out in parallel. Triplicate representative traces are shown for each homozygous
wild-type/variant genotype in each assay. One heterozygous genotype is also shown for each assay.
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der washings from a new cohort of
75 patients undergoing transurethral
resection (TUR). Collection of the
cells from the washings was per-
formed as described previously (5 ),
except that the elaborate enrichment
procedure for urothelial cells was
omitted. RNA isolation and cDNA
synthesis were carried out as de-
scribed previously (5 ). We investi-
gated cDNA quality and quantity in
all samples by measuring the mRNA
expression of the housekeeping gene
cyclophilin A with the cyclophilin A
TaqMan® Endogenous Control re-
agent set (Applied Biosystems), ac-
cording to the manufacturer’s in-
structions. Expression data were
analyzed with Sequence Detector,
Ver. 1.9.1 (Applied Biosystems). We
excluded 27 samples because the cy-
clophilin critical threshold (Ct) val-
ues were 34, indicating insufficient
cDNA quality/quantity for gene ex-
pression analysis of survivin and
MKI67.
We then evaluated pathology re-
ports from the 68 remaining TUR
cases and excluded 11 bladder wash-
ings because they were from patients
who did not present with Ta or T1
urothelial cell carcinoma. The re-
maining group of 47 patients (57
washings) consisted of 36 men and
11 women (mean age, 67 years;
range, 45–82 years; for additional
data, see Table 1 in the Data Supple-
ment that accompanies the online
version of this letter at http://www.
clinchem.org/content/vol52/issue7).
During the follow-up period of 6 to
35 months, 29 patients suffered can-
cer recurrence, 12 within 1 month of
evaluation. The recurrence-free pe-
riod was recorded from the time of
TUR.
We next measured survivin and
MKI67 mRNA expression in the 57
bladder washings. The real-time
quantitative-PCR conditions for sur-
vivin were as published previously
(3 ). MKI67 was measured with the
MKI67 TaqMan Gene Expression As-
say (Assay ID Hs00606991_m1; Ap-
plied Biosystems) according to the
manufacturer’s instructions. Sur-
vivin and MKI67 gene expression
data were normalized with the for-
mula 2(Ct target  Ct cyclophilin A) (8 ).
We investigated the correlation be-
tween survivin and MKI67 mRNA
expression in the bladder washings
with tumor stage and grade of the
corresponding tissue, using theMann–
Whitney U-test (for stage) and the
Kruskal–Wallis test (for grade). The
mRNA expression of both genes
showed a clear correlation with
pathologic characteristics (Fig. 1).
To investigate the relationship be-
tween mRNA expression and the
time to recurrence, we constructed
Kaplan–Meier survival curves for pa-
tients with survivin or MKI67 mRNA
expression below and above the me-
dian and used the log-rank test for
comparison. Neither survivin nor
MKI67 expression correlated with
the recurrence-free period (P  0.88
and 0.21, respectively). Of the vari-
ables tumor stage, grade, and multi-
plicity, only grade showed a relation-
ship with the time to recurrence (P 
0.012).
In contrast to the present results,
we previously had found a correla-
tion between survivin mRNA ex-
pression in bladder washings and
the recurrence-free interval (5 ). In
that study, bladder washings were
enriched for urothelial cells to pre-
vent interference of gene expression
normalization by nonurothelial cells,
especially leukocytes. In the present
study, we omitted the elaborate en-
richment step to simplify the proce-
dure. This omission may have led to
the loss of a correlation between sur-
vivin mRNA expression and the time
to tumor recurrence. The lack of this
correlation may also be related to the
loss of a substantial number of blad-
der washings, which may have influ-
enced the recurrence pattern of the
patient cohort.
Despite the lack of a correlation
with recurrence, we observed a cor-
relation of survivin and MKI67
mRNA expression with the patho-
logic variables tumor stage and
grade. Therefore, even in the absence
of enrichment for urothelial cells,
bladder washings provided an accu-
rate profile of the molecular biologi-
cal status of the urothelium. The in-
dependent prognostic value of tumor
markers assessed in bladder wash-
ings needs further investigation.
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Preanalytic Error Tracking in a
Laboratory Medicine Department:
Results of a 1-Year Experience
To the Editor:
Remarkable advances in technology,
automation, and testing procedures
have produced radical changes in
laboratory organization, granting
major precision and accuracy of test
results. Nevertheless, errors occur-
ring within the whole testing process
still influence the quality of labora-
tory performance. There is heteroge-
neous information on the error rate
within the whole laboratory testing
process (from 0.1% to 9.3%) (1 ).
Moreover, the frequencies and types
of mistakes differ between one facil-
ity and another and between one
time period and another (2 ). Process
analysis has demonstrated that labo-
ratory errors occur primarily in the
preanalytic phase, influencing pa-
tient outcomes and costs (1–3). Com-
pliance with systems of quality man-
agement, such as certification and
accreditation, requires accurate pro-
cedures for identifying the processes
that are more susceptible to errors
(4 ).
The Laboratory Medicine Depart-
ment of the University Hospital of
Verona is a laboratory service pro-
viding stat and routine tests for clin-
ical chemistry, hematology, coagula-
tion, and immunology, serving an
area with a population of 270 000
inhabitants. The laboratory serves a
hospital with 750 beds and special-
ized care units. Inpatient phleboto-
mies are performed by clinical
department staff, whereas blood
specimens from outpatients are col-
lected on site by laboratory person-
nel. After implementation of the new
ISO accreditation guidelines, since
October 2004 the laboratory staff has
been trained to identify and system-
atically record each error encoun-
tered within the global testing
process, particularly preanalytic mis-
takes. Venous blood samples for rou-
tine clinical chemistry (lithium hepa-
rin gel tubes), hematologic (EDTA
tubes), coagulation (buffered sodium
citrate tubes), electrophoresis, spe-
cific protein, and immunology test-
ing (serum gel tubes) were consid-
ered unsuitable according to the
following accepted criteria (5, 6): in-
appropriate volume (excess or deficit
in the volume required to perform
the analysis), wrong or missing pa-
tient identification, inappropriate
container, visible hemolysis after
centrifugation, clotting, and contam-
ination from infusion route. The lab-
oratory staff was provided with a
notebook in which numbers of tubes
and errors were recorded daily, and
the quality referent of our laboratory
systematically discussed and re-
viewed data on a weekly basis.
From October 2004 to September
2005, a total of 423 075 routine ve-
nous blood specimens (71 922 from
outpatients; 17%) were received in
the 5 more representative sections of
our laboratory (130 806 for clinical
chemistry testing, 113 699 for hema-
tologic testing, 61 301 for coagulation
testing, 59 403 for electrophoresis
and specific protein testing, and
57 866 for immunology testing). Ac-
cording to the above specified crite-
ria, 3154 (0.74%) preanalytic errors
were identified and recorded in the
1-year observational period (Table 1).
Errors were related to samples in
which they were relevant. In agree-
ment with earlier data (1, 7), we ob-
served a significant difference in the
error rate between inpatients and
outpatients (0.82% vs 0.37%; 2 test, P
0.001). The most common mistakes
could be traced to incorrect proce-
dures for sample collection, includ-
ing hemolysis and clotting. The
prevalences of other types of errors
were rather different between speci-
mens collected from inpatients and
outpatients. In particular, insufficient
volume was a prevailing cause of
unsuitable specimens for inpatient
samples, whereas the prevalence of
inappropriate containers was partic-
ularly high for outpatient specimens.
Current data on laboratory error
rates are mixed (1 ). In a survey on
outpatient phlebotomy success, most
unsuitable samples resulted from he-
molysis (18.1%), insufficient quantity
(16.0%), and clotting (13.4%) (5 ).
These data are comparable to those
provided by additional investiga-
tions, which confirm that problems
directly related to specimen collec-
tion are the first causes of preanalytic
errors, especially hemolyzed, clotted,
insufficient, and incorrect samples
(1, 7–9). This investigation repre-
sents a logical extension of previous
analyses focused on laboratory er-
rors identified after collection of clin-
ically questionable results in stat de-
partments for a shorter period of
time (2, 8) or involving limited areas
of laboratory testing, such as clinical
chemistry (7 ) and hematology (9 ).
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